GET DAILY SIGNALSSeaStar Medical (ICU): Can the Stock Reach the $8.00 Analyst Target?
Key Takeaways
- The $8.00 target is the most widely cited public price objective for ICU, originating from a single named analyst at Maxim Group, not a multi-analyst consensus.
- ICU's analyst coverage is thin; the one current, attributable target is $8.00, set on May 14, 2026.
- At a recent close near $4.69, reaching $8.00 implies a gain of roughly 70%, a very large move.
- Supporting factors include accelerating QUELIMMUNE adoption, high gross margins, and the adult NEUTRALIZE-AKI pivotal trial.
- Key risks include heavy share dilution, ongoing operating losses, a small cash balance, and reliance on a single commercial product.
How the $8.00 Target Came About
SeaStar Medical Holding Corporation (ICU) does not have the broad sell-side coverage common among larger healthcare firms, so there is no solid multi-analyst consensus to reference. The $8.00 figure comes from the single active, named analyst target: Maxim Group's Anthony Vendetti raised his objective to $8.00 from $6.00 on May 14, 2026, keeping a Buy rating after first-quarter revenue, gross margin, and loss per share beat his estimates. Earlier in 2026, the same target had been trimmed to $6.00 from $10.00 to account for share dilution. Because this is one firm's view rather than a street-wide forecast, it reflects their assessment of the commercial rollout and pipeline.
Where ICU Stands Today and the Path Forward
The stock most recently closed near $4.69 on October 2, 2026, with after-hours and pre-market activity around $4.90 to $4.95 in early October 2026. The 52-week range runs from roughly $2.07 to $7.35. Moving from about $4.69 to $8.00 would require an increase of approximately 70%, a substantial shift for any security and especially challenging for a micro-cap with a market value near $20 million. Progress would hinge on sustained commercial execution in the pediatric market, advancement in the NEUTRALIZE-AKI adult trial, and the ability to fund operations without excessive dilution. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Factors That Could Support a Move Higher
Revenue is expanding rapidly from a small base: full-year 2025 revenue reached about $1.23 million, up from roughly $135,000 in 2024, and trailing twelve-month revenue stands near $1.71 million. Gross margin has been reported above 95%, reflecting a high-value device business. In the first quarter of 2026, the company added seven new QUELIMMUNE customers among top-tier children's hospitals, bringing its total to 17, and management has guided toward roughly $2 million in net product revenue for 2026. The adult opportunity is considerably larger, and the NEUTRALIZE-AKI pivotal trial had enrolled 198 of 339 patients as of mid-2026, with full enrollment targeted by the end of 2026. The SCD has also received FDA Breakthrough Device Designation for six indications, which could support faster development and future commercialization.
Risks That Could Hold the Stock Back
The company is not yet profitable, reporting a trailing twelve-month net loss of roughly $13.6 million, with total cash near $7 million. Continued cash burn may require further equity raises, and dilution remains a material concern: shares outstanding have increased more than fourfold in a year, which is precisely the factor Maxim cited when it previously cut its target. ICU remains a single-product story, with revenue concentrated in QUELIMMUNE, and adult commercialization depends on successful trial results and regulatory clearance that are not assured. As a micro-cap with a negative beta and elevated volatility, the shares can swing sharply on limited news flow, and an RSI reading near 77 after a rapid rally suggests the stock may be stretched in the short term.
Technical Levels Worth Watching
The 52-week high near $7.35 stands as the most important nearby resistance zone, and it sits below the $8.00 objective. A sustained advance toward the target would first need to clear that prior high and then break into territory the stock has not traded in for over a year. On the downside, the 50-day and 200-day moving averages, both near $3.30, form a key support band that has underpinned the recent recovery from the 52-week low near $2.07. The stock's steep single-day gain of about 25% in early October reflects the kind of low-liquidity, sentiment-driven moves that can reverse quickly.
Time Horizon and Key Items to Monitor
A single analyst target of this kind is generally framed around a roughly twelve-month outlook, though the exact horizon is not disclosed in public summaries. Investors should watch the next quarterly report, estimated for November 12, 2026, for updates on QUELIMMUNE customer additions and revenue, the pace of NEUTRALIZE-AKI enrollment, and any commentary on cash runway and potential financing. Reimbursement developments, including the newly available ICD-10-PCS billing codes for SCD therapy, and any FDA milestones for the adult indication will also be relevant to whether the valuation case behind $8.00 strengthens or weakens. From what I see, tracking these elements closely will help clarify the setup.
AI Daily Buy/Sell Signals
In my research process, I often review Tickeron's AI Daily Buy/Sell Signals for an extra data-driven perspective on names like this. The system applies artificial intelligence to scan market conditions, technical behavior, and patterns across thousands of stocks and ETFs, producing Buy, Sell, or Hold signals that can help highlight potential shifts. It serves as a useful screening and monitoring layer alongside independent analysis rather than a replacement for it.
Final Assessment
The $8.00 objective for SeaStar Medical is best understood as a single named analyst's price target rather than a broad consensus, and it implies a gain of roughly 70% from recent levels near $4.69. The case for reaching it rests on rapid revenue growth, high-margin device economics, expanding pediatric adoption, and the larger adult pipeline opportunity. The case against it centers on persistent losses, a limited cash position, heavy dilution, and execution risk in both the commercial launch and the pivotal adult trial. With the 52-week high near $7.35 acting as a meaningful hurdle just below the target, investors should focus on quarterly results, trial enrollment, and financing decisions before drawing conclusions. No outcome is assured, and the target represents a research viewpoint, not a forecast of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ICU in downward trend: 10-day moving average broke below 50-day moving average on October 21, 2026
The 10-day moving average for ICU crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ICU as a result. In 80 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for ICU turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 34 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
ICU moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for ICU moved below the 200-day moving average on October 20, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ICU entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for ICU's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICU advanced for three days, in 150 of 183 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ICU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.929) is normal, around the industry mean (3.498). P/E Ratio (-0.995) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.468) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. ICU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement